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The invention of atomic force microscopy (AFM) has provided new technology for measuring specific molecular interaction 
forces. Using AFM single-molecule force spectroscopy (SMFS) techniques, CD20-Rituximab rupture forces were measured on 
purified CD20 proteins, Raji cells, and lymphoma patient B cells. Rituximab molecules were linked onto AFM tips using AFM 
probe functionalization technology, and purified CD20 proteins were attached to mica using substrate functionalization technolo-
gy. Raji cells (a lymphoma cell line) or lymphoma patient cells were immobilized on a glass substrate via electrostatic adsorption 
and chemical fixation. The topography of the purified CD20 proteins, Raji cells, and patient lymphoma cells was visualized using 
AFM imaging and the differences in the rupture forces were analyzed and measured. The results showed that the rupture forces 
between the CD20 proteins on Raji cells and Rituximab were markedly smaller than those for purified CD20 proteins and CD20 
proteins on lymphoma patient B cells. These findings provide an effective experimental method for investigating the mechanisms 
underlying the variable efficacy of Rituximab. 
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The invention of atomic force microscopy (AFM) [1] allows 
researchers to investigate the topographical structure and 
specific molecular interactions between individual live cells 
and molecules, thereby revolutionizing the research meth-
ods used in the field of life sciences. The resolution of light 
microscopy is limited to the wavelength of the light source 
and, therefore, information on a nanometer scale is not ac-
cessible; also, electron microscopy requires vacuum condi-
tions, which means that live samples cannot be examined 
using this technique [2]. Compared with light microscopy 
and electron microscopy, AFM has sub-nanometer resolu-
tion [3], can work under various conditions such as air,  
liquid, and/or a vacuum, and allows the visualization of live 
cells and native biomolecules without the need for staining 
or fixation [4]. These advantages make AFM widely appli-
cable to life sciences, a field in which research into individ-
ual cells/molecules using AFM is at the frontier [5–7]. 
As a result of significant advances over the last two de- 
cades, AFM has evolved into a multifunctional tool [4]. 
Chemical treatment of the AFM tip and substrate allows the 
measurement of specific protein-protein binding forces us-
ing the force curve mode, a technique known as single- 
molecule force spectroscopy (SMFS) [8]. In SMFS, li- 
gands/antibodies are linked to AFM tips and recep-
tors/antigens are then bound to a substrate. Using the func-
tionalized tip to obtain force curves for the protein-coated 
3830 Li M, et al.   Chinese Sci Bull   December (2011) Vol.56 No.35 
substrate, the rupture forces between the antibody-     
antigen/receptor-ligand can be measured. SMFS was first 
used in the mid-1990s. Florin et al. [9] measured the rupture 
force for the biotin-avidin complex immobilized on bioti-
nylated agarose beads by linking avidin to the AFM tip. 
Hinterdorfer et al. [10] measured the rupture force between 
human serum albumin (HSA) and anti-HSA by linking the 
anti-HSA onto an AFM tip using polyethylene glycol (PEG) 
linker molecules and linking HSA onto mica surfaces. In 
addition to measuring the molecular forces between pro-
tein-coated substrates, SMFS can also measure molecular 
forces at the cell surface. Puntheeranurak et al. [11] meas-
ured the specific binding forces between the Na+-glucose 
co-transporter (SGLT1) to its antibodies on Chinese ham-
ster ovary (CHO) cells, and Shi et al. [12] investigated the 
interaction forces between Heregulin and HER3 on human 
embryonic kidney (HEK) 293 cells. 
The clinical application of Rituximab (a monoclonal an-
tibody against CD20) during the last decade has highlighted 
a marked difference in efficacy in the treatment of patients 
with non-Hodgkin’s lymphoma [13]. The target of Rituxi-
mab is the CD20 antigen, which is a tetra-spanning mem-
brane protein expressed on mature B cells and by most B 
cell lymphomas [14]. After binding to CD20 on the cell 
surface, Rituximab induces target cell lysis via anti-
body-dependent cellular cytotoxicity (ADCC), comple-
ment-dependent cytotoxicity (CDC), and programmed cell 
death (PCD) [15]. Rituximab achieved unprecedented suc-
cess and, particularly in combination with chemotherapy, 
significantly improved the survival rates of lymphoma pa-
tients [16]. However, owing to its varying efficacy in dif-
ferent patients, there is an urgent need for improvement [13]. 
A better understanding of the mechanisms underlying 
Rituximab-mediated cell death should make it possible to 
develop new and more effective therapeutic agents [17]. In 
the present study, the specific CD20-Rituximab recognition 
interactions were investigated, and the rupture forces be-
tween Rituximab and purified CD20 proteins, CD20 pro-
teins expressed by Raji cells, and CD20 proteins expressed 
by lymphoma patient B cells were measured using SMFS. 
The results may pave the way for further investigations into 
the relationship between the variable efficacy of Rituximab 
and CD20-Rituximab interaction forces. 
1  Principle 
The principle behind measuring the CD20-Rituximab rup-
ture forces is shown in Figure 1. Rituximab was linked onto 
the AFM tip via a PEG linker molecule. To measure the 
rupture forces between the purified CD20 proteins and 
Rituximab, the CD20 proteins were attached to a mica sub-
strate (Figure 1(a)). When measuring the rupture forces be-
tween Rituximab and the CD20 proteins expressed on lym-
phoma cells, lymphoma cells were immobilized on a glass 
surface via electrostatic adsorption and chemical fixation 
(Figure 1(b)). During the force curve mode, the probe 
slowly approaches and contacts the substrate/cell, causing 
the Rituximab molecules on the tip to bind to the CD20 
molecules on the substrate/cell and form CD20-Rituximab 
complexes. The probe then retracts from the substrate/cell. 
The CD20-Rituximab complexes dissociate when the force 
exerted by the probe is equal to the CD20-Rituximab rup-
ture force. By recording the displacement of the piezo tube 
and the deflection of the probe cantilever during the ap-
proach-retract cycle, force-distance curves can be con-
structed (Figure 1(c)). Each force curve comprises two por-
tions: the approach curve and the retract curve. If the 
CD20-Rituximab binding events occur during the approach, 
there is an abrupt peak in the retract portion of the force 
curve. The abrupt peak corresponds to the dissociation of 
the CD20-Rituximab complexes. By analyzing these force 
curves, individual CD20-Rituximab rupture forces can be 
calculated. 
2  Materials and methods 
2.1  Materials 
Rituximab (10 mg/mL) was obtained from the Chinese Af-
filiated Hospital of the Military Medical Academy of Sci-
ences. N-hydroxysuccinimide-polyethylene glycol-Maleimide 
(NHS-PEG-MAL, MW 2000) was purchased from JenKem 
(China). Functionalization reagents were purchased from 
 
 
Figure 1  Principles behind the measurement of CD20-Rituximab rupture forces using SMFS. (a) Measuring the forces on purified CD20 proteins. (b) 
Measuring the forces on lymphoma cells. (c) The force curve. 
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Sigma-Aldrich (USA), including aminopropyltriethox-
ysilane (APTES), N,N-diisopropylethylamine, triethylamine, 
and phosphate buffered saline (PBS), or from J & K (China), 
including hydroxylamine, chloroform, dimethyl sulfoxide 
(DMSO), and N-Succinimidyl 3-(Acetylthio) propionate 
(SATP). Poly-L-lysine and glutaraldehyde were purchased 
from Solarbio Science and Technology Co. (China). CD20 
proteins were purchased from Huaruikang Company (Chi-
na). Milli-Q ultra-pure water (18.2 MΩ cm) was used for all 
experiments. 
2.2  Protein and cell immobilization 
CD20 proteins were attached to freshly cleaved mica (1 cm 
× 1 cm squares) according to established procedures [18]. A 
glass desiccator was purged with argon for 2 min. APTES 
(30 μL) was pipetted into a small petri dish and N,N-  
diisopropylethylamine (10 μL) was pipetted into another 
small petri dish. The freshly cleaved mica and the two petri 
dishes were placed in the glass desiccator, purged with ar-
gon for 2 min, and sealed for 0.5–2 h to allow the APTES 
vapor to mix with the N,N-diisopropylethylamine vapor and 
coat a layer of –NH2 onto the AFM probe surface. Glutar-
aldehyde solution (200 μL) was then added to the mica and 
incubated for 10 min (the glutaraldehyde reacts with the 
NH2 on the tip surface) [18]. The mica was then rinsed with 
Milli-Q ultra-pure water. CD20 protein solution (100 μL) 
was added to the mica and incubated for 30 min. The mica 
was then rinsed with Milli-Q ultra-pure water again and 
placed in a petri dish with PBS prior to probing by AFM. 
Raji cells (a Burkitt’s lymphoma cell line) were cultured 
in RPMI-1640 culture medium containing 10% fetal bovine 
serum at 37°C (in 5% CO2). The cells were attached to glass 
slides via poly-L-lysine-induced electrostatic adsorption and 
glutaraldehyde chemical fixation. In brief, the glass slides 
were coated with poly-L-lysine and stored at room temper-
ature overnight. Cells were harvested by centrifuging at 
1000 r/min and a drop of the cell suspension placed onto a 
glass slide. After 30 min, the cells were fixed with 0.25% 
glutaraldehyde for 15 min and the slide placed in a petri 
dish with PBS for the AFM experiments. 
Lymphoma patient samples were prepared from the bone 
marrow of a B lymphoma patient. A paracentesis needle 
was used to acquire the bone marrow, which was then add-
ed to the poly-L-lysine-coated glass slides. A fresh glass 
slide was used to disperse the bone marrow and 4% for-
maldehyde was used for chemical fixation. 
2.3  Probe functionalization 
The heterobifunctional linker, NHS-PEG-MAL, was used to 
tether Rituximab to the AFM stylus. This linker contains an 
NHS ester at one end and a MAL ester at the other. The 
stylus functionalization process followed was performed 
according to established procedures [19]. APTES (30 μL) 
and N,N-diisopropylethylamine (10 μL) were used to coat 
the AFM stylus with -NH2 groups under argon gas in a glass 
desiccator for 0.5–2 h. The PEG linker and triethylamine 
were mixed in chloroform and then incubated with the 
NH2-modified probes for 2–3 h. Rituximab was treated with 
SATP to form thiol functional groups (the thiols react with 
the MAL end of the PEG linker) [20]. Finally the probes 
were placed in the SATP-Rituximab mixture containing 
hydroxylamine and buffer solution (pH 7.5) for 1 h. The 
functionalized probes were stored in PBS at 4°C. 
2.4  AFM imaging and measurements 
AFM imaging and measurements were performed using a 
Dimension 3100 AFM and a MultiMode AFM (Veeco AFM, 
Santa Barbara, CA, USA) with silicon nitride probes (0.06 
N/m). The spring constant was calibrated using a Thermal 
Tune Adapter (Veeco AFM). All experiments were per-
formed in PBS at room temperature. Non-functionalized 
probes were used to visualize the topography of the CD20 
proteins (MultiMode AFM), lymphoma Raji cells (Dimen-
sion 3100 AFM), and lymphoma patient cells (Dimension 
3100 AFM). The imaging mode used was “contact mode”, 
the scan force was 50 pN, and the scan rate was 1 Hz. 
Measurement of the CD20-Rituximab rupture forces was 
performed using the Dimension 3100 AFM. Approximately 
500 force curves (at the same loading rate of 1.99 μm/s) 
were obtained for the CD20 proteins, Raji cells, and lym-
phoma patient B cells using force curve mode and function-
alized probes. Blocking experiments [21] were used to ver-
ify the specific CD20-Rituximab binding forces. Free 
Rituximab was then added to mask the CD20 molecules on 
the substrate/cell, and force curve obtained gain about 30 
min later. 
2.5  Poisson analysis 
Several CD20-Rituximab complexes may be formed during 
the process of obtaining the force curves. Therefore, Pois-
son analysis [22] was used to calculate individual CD20- 
Rituximab rupture forces using the following formula: 
 
2
,F

   (1) 
in which 2 and  represent the variance and mean, respec-
tively, for one measurement, and F is the binding force. If 
several measurements at the same loading rate are per-
formed, the variance can be plotted against the mean. The 
individual CD20-Rituximab rupture force is equal to the 
slope of the fitted line. 
3  Results and discussion 
Figure 2 shows the results of measuring the rupture forces 
between purified CD20 proteins and Rituximab. After  
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Figure 2  Measurement of the rupture force between purified CD20 proteins and Rituximab. (a) AFM contact mode topography image of CD20 proteins. (b) 
AFM contact mode deflection image of CD20 protein. (c) A typical force curve. (d) Force curve after adding free Rituximab. (e) Histogram showing the 
rupture forces. (f) Poisson analysis was used to calculate the individual rupture forces. 
treating the mica with APTES and glutaraldehyde, the ex-
posed aldehydes react with the lysine residues [18]. The 
CD20 proteins contain lysine residues and, therefore, are 
cross-linked onto the mica. Figure 2(a) and (b) shows the 
AFM contact mode images obtained for the purified CD20 
proteins. The scan size was 1.5 μm. Figure 2(a) shows the 
topography image and Figure 2(b) shows the deflection im-
age. Many CD20 protein particles can be seen distributed 
over the mica surface. A prerequisite of imaging proteins in 
fluids is their attachment to a flat support [23]; mica is the 
most commonly used support because of its atomically flat 
surface and ease of preparation [24]. However, the intrinsic 
hydrophobicity of proteins means that they are difficult to 
attach to mica, which is hydrophilic [25]. Various methods, 
including physical adsorption and covalent attachment, have 
been used to attach proteins to mica surfaces [26]. Hender-
son et al. [25] imaged individual ROMK1 proteins by coat-
ing the mica with cetylpyridinium chloride, and Kada et al. 
[27] used AFM to visualize individual ryanodine receptors 
adsorbed onto mica surfaces in the presence of Ca2+.  
Wang et al. [28] imaged IgG4 proteins by treating the mica 
with APTES and glutaraldehyde. However, because of the 
soft, fragile, corrugated and dynamic nature of the cell sur-
face, visualizing the topography of individual receptors on 
living mammalian cells is still a challenge [29], and 
co-operation between experts from different scientific dis-
ciplines is essential to achieve this goal. 
A typical force curve obtained using CD20-coated mica 
and a Rituximab-conjugated a probe is shown in Figure 2(c). 
The dotted line indicates the approach process and the solid 
line indicates the retraction process. An abrupt peak is visi-
ble on the retract curve. When performing the functionaliza-
tion experiments, the bonds between AFM tip and PEG 
linker molecule, the bonds between Rituximab and the PEG 
linker molecule, and the bonds between the CD20 and the 
substrate should be much stronger than the bonds between 
CD20 and Rituximab. Research indicates that the bonds 
between the NHS end of the PEG linker and the AFM tip 
are much stronger than protein-protein interactions [10,21]. 
Additionally, the bonds between the MAL end of the PEG 
linker and the antibody, and the bonds between proteins and 
the aldehyde group on the functionalized mica are much 
stronger than protein-protein interactions [20,28]. Therefore, 
during the process of stretching the CD20-Rituximab com-
plex in the force curve mode, the CD20-Rituximab complex 
ruptures first. When force curves were obtained again after 
adding free Rituximab, no peaks were visible on the retract 
curve (Figure 2(d)). This confirmed that the peak in Figure 
2(c) corresponded to the specific binding between CD20 
proteins on the mica and the Rituximab on the AFM tip. 
After calculating the rupture forces for each force curve 
obtained on the mica, a histogram of the rupture forces was 
constructed (Figure 2(e)). Gaussian fitting of the histogram 
indicated that the rupture force was 182±69 pN. The mean 
and variance were calculated for 5 measurements. The 
means were 0.2053, 0.1814, 0.2035, 0.2353, and 0.2047, 
and the variances were 0.0063, 0.0024, 0.0023, 0.0087, and 
0.0056. The fitting function used was f(x) =p1×x+p2, and the 
results indicated that p1 = 0.1205 and p2=0.01977. The 
slope of the fitting line indicated that the individual rupture 
force was 121 pN (Figure 2(f)). 
Figure 3 shows the rupture forces between CD20 pro-
teins expressed by Raji cells and Rituximab. Figure 3(a) 
shows the contact mode topography image. The scan size 
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Figure 3  Measurement of the rupture force between CD20 proteins on Raji cells and Rituximab. (a) AFM contact mode topography image of Raji cells. (b) 
AFM contact mode topography image of the local area of the Raji cell. (c) A typical force curve. (d) Force curve after adding free Rituximab. (e) Histogram 
of the rupture forces. (f) Poisson analysis was used to calculate the individual rupture forces. 
was 40 μm. To visualize the topography of the local cell 
surface, the scan size was reduced to 3 μm. Figure 3(b) 
shows the topography image of the local area. From these 
images, it can be seen that the cell surface is corrugated and 
rough. A typical force curve obtained using Raji cells and a 
Rituximab-conjugated probe is shown in Figure 3(c). There 
is an abrupt peak on the retract curve, which disappears 
after the addition of free Rituximab (Figure 3(d)). This con-
firmed the specific CD20-Rituximab binding interactions. 
Figure 3(e) shows the histogram of the rupture forces. 
Gaussian fitting indicated that the rupture force was 162±71 
pN. For five individual measurements, the means were 
0.1787, 0.2859, 0.2033, 0.1690, and 0.2493, and the vari-
ances were 0.0060, 0.0153, 0.0043, 0.0017, and 0.0059. The 
fitting function used was f(x) = p1×x+ p2 and the fitting re-
sults indicated that p1 = 0.08888 and p2=-0.01267. The slope 
of the fitted line on the plot of variance against the mean 
indicated that the individual rupture force was 89 pN (Fig-
ure 3(f)). 
Figure 4 shows the results of measuring the rupture forc-
es between CD20 proteins on lymphoma patient B cells and 
Rituximab. Figure 4(a) and (b) shows the contact mode 
AFM images of lymphoma patient cells. Figure 4(a) shows 
the topography image and Figure 4(b) shows the deflection 
image. The scan size was 50 μm. Many red blood cells can 
be seen among the patient cells. CD20 is expressed on B 
cells, but not expressed on red blood cells. To measure the 
CD20-Rituximab rupture forces on patient B cells, the func-
tionalized probe was first used to scan a large area (Figure 
4(c)). Then, several cells were randomly selected and force 
curves obtained. If no abrupt peaks were visible in the force 
curves obtained for an individual cell (Figure 4(c), I), the 
cell was discarded. If abrupt peaks were visible in the force 
curves (Figure 4(c), II and III), the cell was selected and the 
CD20-Rituximab rupture forces were measured (about 100 
force curves were obtained). The inset in Figure 4(d) shows 
a histogram of the rupture forces. Gaussian fitting indicated 
that the rupture force was 180±90 pN. For 6 measurements, 
the means were 0.1302, 0.1981, 0.2204, 0.2909, 0.4548, and 
0.4936, and the variances were 0.0044, 0.0082, 0.0183, 
0.029, 0.0403, and 0.0529. The fitting function used was f(x) 
= p1×x+p2 and the fitting results indicated that p1 = 0.1259 
and p2 = 0.01199. The slope of the fitted line on the plot of 
variance against the mean indicated that the individual rup-
ture force was 126 pN (Figure 4(d)). 
After analyzing and measuring the CD20-Rituximab 
rupture forces on purified CD20 proteins, CD20 proteins on 
Raji cells, and CD20 proteins on lymphoma patient B cells, 
we can see that the rupture force of the purified CD20 pro-
teins was 182±69 pN, that of the CD20 proteins on Raji 
cells was 162±71 pN, and that of the CD20 proteins on 
lymphoma patient B cells was 180±90 pN. As mentioned 
above, several CD20-Rituximab complexes may form dur-
ing the measurement process and, after Poisson analysis, the 
individual CD20-Rituximab rupture forces for the purified 
CD20 proteins, CD20 proteins on Raji cells, and CD20 pro-
teins on lymphoma patient B cells were calculated to be 121, 
89, and 126 pN, respectively. Combing the histogram re-
sults and Poisson analysis results shows that the rupture 
force for CD20 proteins on Raji cells was the lowest, and 
the rupture force for the purified CD20 proteins was similar 
to that for CD20 proteins on lymphoma patient B cells. It 
should be noted that the Raji cells were cultured in vitro, 
and it is known that cells grown in a flat 2-D environments  
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Figure 4  Measurement of the rupture force between CD20 proteins on the lymphoma patient cells and Rituximab. (a) AFM contact mode topography 
image of patient cells. (b) AFM contact mode deflection image of patient cells. (c) Method of measuring the CD20-Rituximab rupture forces on patient cells.     
(d) Poisson analysis was used to calculate the individual rupture force. (Inset) histogram showing the rupture forces. 
differ considerably their structure and function from those 
grown in a 3-D in vivo environments [30]. This may be why 
the rupture forces for CD20 proteins on Raji cells and the 
CD20 proteins on patient B cells were different in this study. 
Additionally, CD20 proteins expressed on prokaryotic cells 
in vitro do not completely correspond to natural human 
CD20 proteins in vivo. For mammalian proteins, a mamma-
lian expression system is likely to give the best results in 
terms of protein structure and function [31]. The difference 
between the in vitro and in vivo environment may result in 
differences between proteins, and these differences may 
account for the rupture forces measured for the purified 
CD20 proteins and CD20 proteins on Raji cells. These re-
sults indicate that, if we are to thoroughly investigate the 
mechanisms underlying the variable efficacy of Rituximab, 
experiments should be performed using cells from lym-
phoma patients. Recently, AFM research on patient cells 
indicated that the distribution of CD20 molecules on B cells 
from healthy volunteers was uniform, whereas that on B 
cells from B-CLL patients was relatively sparse [32]. Gu et 
al. [33] suggested that the binding force between CD20 and 
anti-CD20 is closely associated with the linker peptide. 
However, the in vivo mechanism of action of Rituximab is 
still unknown [15], knowledge a regarding its variable effi-
cacy is scarce, and further study is required to elucidate the 
underlying mechanisms. 
4  Conclusions 
More effective, targeted drugs are urgently needed for 
Rituximab-targeted therapy of B-cell non-Hodgkin’s lym-
phoma because of the variable efficacy observed between 
lymphoma patients. AFM SMFS provides a new method for 
investigating specific molecular interactions and can be 
used to obtain new knowledge about the molecular interac-
tions at the level of individual cells/molecules. The rupture 
forces between Rituximab and purified CD20 proteins, 
CD20 proteins on Raji cells, and CD20 proteins on lym-
phoma patient B cells were measured using AFM SMFS 
and the differences between the rupture forces analyzed. In 
addition, the topography of the purified CD20 proteins, Raji 
cells, and lymphoma patient B cells was visualized. The 
results indicated that the rupture force between CD20 pro-
teins on Raji cells and Rituximab was the lowest (89 pN), 
whereas that between purified CD20 proteins (121 pN) was 
similar to that for the CD20 proteins on lymphoma patient B 
cells (126 pN). These results provide the foundation for 
further investigations into the molecular mechanism under-
lying the variable efficacy of Rituximab, and may provide a 
key technology that can be used to develop the next genera-
tion of monoclonal antibody drugs. 
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